Gilead Receives Criticism For Efforts To Keep Generic HCV Drug From Being Diverted To Developed Countries

Financial Times: Pharma combats diversion of cheap drugs
“…[A]s the first Indian-made generics [of Gilead’s hepatitis C drug Solvadi] start to roll off the production lines, Gilead is coming in for heavy criticism. Médecins Sans Frontières, the medical charity, is accusing the U.S. group of promoting overly-intrusive patient surveillance to stop the generic, called sofosbuvir, being diverted to patients in developed countries where the drug is more costly and tightly rationed by strained public health systems…” (Kazman, 4/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.